机译:高级实体肿瘤患者Avelumab的安全谱:来自第1阶段标枪实体肿瘤和第2阶段Javelin Merkel 200临床试验的汇总分析
Department of Internal MedicineUniversity of California‐Davis Comprehensive Cancer CenterSacramento;
Sarah Cannon Research Institute/Tennessee OncologyPLLCNorth Nashville Tennessee;
Oregon Health and Science University Knight Cancer InstitutePortland Oregon;
Sarah Cannon Research Institute/Florida Cancer SpecialistsSarasota Florida;
Department of MedicineUniversity of California at Los AngelesLos Angeles California;
Hematology Oncology Associates of the Treasure CoastPort St. Lucie Florida;
Division of Medical Oncology Rutgers Cancer Institute of New Jersey Rutgers Robert Wood Johnson;
Merck KGaADarmstadt Germany;
Merck KGaADarmstadt Germany;
Merck KGaADarmstadt Germany;
Genitourinary Malignancies Branch Laboratory of Tumor Immunology and Biology Center for Cancer;
avelumab; immunotherapy; JAVELIN; programmed death‐ligand 1 (PD‐L1); safety;
机译:高级实体肿瘤患者Avelumab的安全谱:来自第1阶段标枪实体肿瘤和第2阶段Javelin Merkel 200临床试验的汇总分析
机译:Avelumab用于转移性或局部先进的先前处理的实体肿瘤(标枪实体瘤):1A,多射点,剂量升级试验
机译:先进的非小细胞肺癌患者一线Avelumab的疗效和安全性:标枪固体瘤研究的IB队队列的结果
机译:患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
机译:长春新碱,伊非替康,替莫唑胺和贝伐单抗(VIT-B)逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
机译:avelumab在晚期实体瘤患者中的安全性概况:JAVELIN 1期实体瘤和2 JAVELIN Merkel 200期临床试验数据的汇总分析
机译:日本先进实体瘤患者中Avelumab(抗PD-L1)的第1阶段试验,包括胃或胃食管癌患者的剂量扩张:标枪实体瘤JPN试验